Journal article
Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
S Horwitz, B Coiffier, F Foss, HM Prince, L Sokol, M Greenwood, D Caballero, F Morschhauser, L Pinter-Brown, SP Iyer, A Shustov, J Nichols, J Balser, B Balser, B Pro
Annals of Oncology | Published : 2015
Abstract
Background: For patients with peripheral T-cell lymphoma (PTCL), the value of 18fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The utility of FDG-PET, in addition to conventional radiology, was examined as a planned exploratory end point in the pivotal phase 2 trial of romidepsin for the treatment of relapsed/refractory PTCL. Patients and methods: Patients received romidepsin at a dose of 14 mg/m2 on days 1, 8, and 15 of 28-day cycles. The primary end point was the rate of confirmed/unconfirmed complete response (CR/CRu) as assessed by International Workshop Criteria (IWC) using conventional radiology. For t..
View full abstractGrants
Awarded by National Center for Advancing Translational Sciences
Funding Acknowledgements
The GPI-06-0002 study was supported by funding from Celgene Corporation (no grant numbers apply).